BO
Boiron S.A.
BOIRF · OTC
$31.50 +0.00% (+$0.00)
Market Cap 450.3M €
P/E Ratio 39.90x
Div. Yield 4.54%
ROE -
Bulios Fair Price
$21.37
32.2% downside
Current Price
$31.5
Undervalued Fair Value Overvalued
According to Bulios Fair Price, BOIRF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
6/9Valuation
71 /100
Cheap P/E 39.90x
EV/EBITDA 6.89x
P/S 0.92x
Growth
45 /100
Stable EPS growth 3.47%
Rev. growth 1.39%
FCF growth 44.35%
Profitability
39 /100
Moderate Gross margin 73.58%
Net margin 2.33%
Op. margin 3.23%
Quality
26 /100
Poor ROIC 2.61%
ROA 1.97%
Asset turnover 0.85x
Debt
100 /100
Low Debt/Equity 0.04x
Current ratio 2.51x
Int. coverage 12.96x
Stability
50 /100
Moderate Beta 0.22x
Rev. volatility 15.66%
EPS volatility 46.53%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about BOIRF
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Pascal Houdayer
Employees
2,634
Headquarters
Messimy